Loading
Directs Penn's cancer centre and pioneered CD40 agonist immunotherapy for pancreatic cancer.
Robert H. Vonderheide is Director of the Abramson Cancer Center at the University of Pennsylvania. He is a physician-scientist who pioneered CD40 agonist immunotherapy for pancreatic cancer, showing that CD40 activation can license macrophages and T cells against pancreatic tumours. His selected paper reports that CD40 agonists alter tumour stroma and show efficacy against pancreatic carcinoma in mice and humans. That work led to clinical trials of CD40 agonists with chemotherapy and PD-1 blockade, and he continues to study tumour immunology while directing Penn's cancer centre.
| Title | Journal | Year |
|---|---|---|
| CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Science | 2011 |
It is the evidence that PALB2 and somatic BRCA2 belong in the PARP inhibitor conversation even though the olaparib label stops at germline BRCA.
The clearest statement of why the corpus records so many negative immunotherapy trials here, and of the design logic behind the vaccine and agonist combinations now in trials.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
Shares Cytokines & engineered cytokines, Pancreatic ductal adenocarcinoma.
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.